Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers

In This Article:

NEW YORK, November 19, 2024--(BUSINESS WIRE)--The BlackRock closed-end funds (the "Funds") listed below announced today the expiration and preliminary results of each Fund’s tender offer (each, a "Tender Offer") for up to 2.5% of its outstanding common shares (the "Shares").

Each Tender Offer commenced on October 16, 2024 and expired at 5:00 p.m. Eastern time on November 18, 2024.

Based on preliminary information, the number of Shares properly tendered for each Fund and not withdrawn is noted in the table below.

Fund Name

Ticker

CUSIP

Shares Offered for Repurchase

Shares Tendered (Preliminary Results)

BlackRock Health Sciences Term Trust

BMEZ

09260E105

2,596,285

21,043,412

BlackRock Health Sciences Trust

BME

09250W107

339,884

1,360,222

BlackRock Enhanced International Dividend Trust

BGY

092524107

2,444,126

33,315,326

Based on the preliminary results shown above, because the Tender Offer was oversubscribed for each Fund, the relative number of Shares that will be purchased from each shareholder is expected to be prorated based on the number of Shares properly tendered for the Fund. The purchase price of properly tendered and accepted Shares for each Fund will be 98% of the Fund's net asset value ("NAV") as of the close of regular trading on the New York Stock Exchange on November 19, 2024, the business day immediately following the expiration date of the Tender Offer. The above-indicated results are based on preliminary information, are subject to adjustment and should not be regarded as final. Each Fund expects to announce the final results of its Tender Offer, including the pro-ration factor, if applicable, on or about November 19, 2024.

Questions regarding the Tender Offers may be directed to Georgeson LLC, the Information Agent for the Tender Offers, toll free at the numbers disclosed in each Fund’s Offer to Purchase.

Important Notice

This press release is for informational purposes only and shall not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell any common shares of the Funds. The offer to purchase a Fund’s common shares was made only pursuant to an offer to purchase, a related letter of transmittal and other documents filed with the U.S. Securities and Exchange Commission ("SEC") as exhibits to a tender offer statement on Schedule TO. Shareholders may obtain a free copy of the offer to purchase and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the applicable Fund.